Why Is Eli Lilly Climbing?

Before you go, we thought you'd like these...
Before you go close icon

In this video, health-care analyst David Williamson discusses Eli Lilly and its surprising accomplishment of hitting a new 52-week high despite poor trial results for Alzheimer's drug solanezumab. What is propelling shares forward? Watch and find out along with David's take on the recent developments.

Profiting from our increasingly global economy can be as easy as investing in your own backyard. Our free report "3 American Companies Set to Dominate the World" shows you how. Click here to get your free copy before it's gone.

The article Why Is Eli Lilly Climbing? originally appeared on Fool.com.

Dave Williamson and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Elan and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners